Sleep medicine最新文献

{"title":"Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.","authors":"Chisom Kanu, Shraddha Shinde, Sujatro Chakladar, Ellen B Dennehy, Terri E Weaver, Jiat Ling Poon, Atul Malhotra","doi":"10.1016/j.sleep.2025.106719","DOIUrl":"10.1016/j.sleep.2025.106719","url":null,"abstract":"<p><strong>Aim: </strong>In the phase 3 SURMOUNT-OSA trials, tirzepatide treatment significantly reduced the apnea-hypopnea index (AHI) among people with moderate-to-severe obstructive sleep apnea (OSA) and obesity. We evaluated effects of tirzepatide treatment on sleep disturbance, sleep-related impairment, functioning, health-related quality of life (HRQoL), and OSA symptoms in SURMOUNT-OSA participants.</p><p><strong>Methods: </strong>SURMOUNT-OSA consisted of two randomized, placebo-controlled trials of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks in participants with moderate-to-severe OSA and obesity. For participants using PAP (Study 2), PAP was withdrawn prior to assessments of polysomnography and patient-reported outcome measures (PROMs). Prespecified PROM endpoints were from baseline to Week 52. Changes in sleep-related impairment, sleep disturbance, excessive daytime sleepiness, functioning, and HRQoL were assessed using analysis of covariance. Categorical shifts in OSA symptom severity were described.</p><p><strong>Results: </strong>At Week 52, compared with placebo, tirzepatide-treated participants reported significantly improved Patient-Reported Outcomes Measurement Information System (PROMIS) Short-Form Sleep-related Impairment 8a scores, PROMIS Short-Form v1.0 Sleep Disturbance 8b scores, Functional Outcomes of Sleep Questionnaire Activity-Level scores, EQ-5D-5L scores, and most domains of the Short-Form 36 Health Survey, Version 2. Tirzepatide treatment was also associated with greater improvements in Patient Global Impression of Status and Patient Global Impression of Change symptom scales compared with placebo. Additionally, Study 1 participants reported significant changes in Epworth Sleepiness Scale scores.</p><p><strong>Conclusion: </strong>Results indicate that in addition to objective outcomes of improved AHI, hypoxic burden associated with OSA, and cardiovascular risk factors, people with OSA reported benefits in symptoms, functioning, and HRQoL following tirzepatide treatment.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov number: </strong>NCT05412004.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"106719"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144800313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interplay of dyadic adjustment, sleep quality, and CPAP adherence in OSAS: A cross-sectional study on illness perceptions and depressive symptoms.","authors":"Valentina Poletti, Elvia Battaglia, Paolo Banfi, Eleonora Volpato","doi":"10.1016/j.sleep.2025.106726","DOIUrl":"10.1016/j.sleep.2025.106726","url":null,"abstract":"<p><p>Obstructive Sleep Apnea Syndrome (OSAS) is a prevalent sleep disorder characterized by recurrent upper airway obstructions, leading to adverse health outcomes. Continuous Positive Airway Pressure (CPAP) therapy is the primary treatment, yet adherence remains suboptimal due to psychosocial a nd relational factors. Bed partners often experience sleep disturbances and can influence the patient's treatment adherence. While dyadic adjustment is known to be associated with sleep quality, its role in OSAS management remains underexplored. Illness perceptions and depressive symptoms may mediate the relationship between dyadic adjustment, sleep, and CPAP adherence. This study explored: (1) how dyadic adjustment relates to sleep quality and illness perceptions in couples coping with OSAS; (2) whether illness perceptions mediate the link between dyadic adjustment and sleep disruption; (3) whether depressive symptoms mediate the association between CPAP adherence and relationship quality; and (4) how illness perceptions and depressive symptoms interrelate in OSA management. A cross-sectional study was conducted on 123 dyads (OSAS patients and their bed partners). Participants completed validated measures assessing dyadic adjustment, illness perceptions, sleep quality, depressive symptoms, and CPAP adherence. Actor-Partner Interdependence Mediation Models (APIMeM) and mediation analyses were applied. Higher dyadic adjustment was associated with less threatening illness perceptions, which in turn predicted fewer perceived sleep disturbances in patients (p < 0.001). No significant partner effects emerged for sleep quality. Higher CPAP use was directly associated with improved dyadic adjustment, with depressive symptoms mediating this relationship (β = 0.35, p < 0.001). Illness perceptions were positively correlated with depressive symptoms in both patients and partners. Dyadic adjustment and illness perceptions shape sleep experiences, while depressive symptoms influence the CPAP adherence-relationship quality link. The interplay between cognitive and emotional factors may have clinical relevance for treatment adherence and couple adaptation. Psychosocial interventions targeting relationship dynamics and illness representations may enhance both adherence and overall well-being, fostering a more supportive treatment environment.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"106726"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep-related disruptions potentially synergistically exacerbate attentional impairments in temporal lobe epilepsy, especially the alerting network.","authors":"Yiting Ding, Weiting Tang, Zengzhen Yin, Zhongling Wu, Haojun Yang","doi":"10.1016/j.sleep.2025.106731","DOIUrl":"10.1016/j.sleep.2025.106731","url":null,"abstract":"<p><strong>Aim: </strong>To explore the potential synergistic effect of sleep-related disruptions (SRD) on attention dysfunction in temporal lobe epilepsy (TLE), focusing on how SRD impacts specific attention networks, including alertness, orientation, and executive control.</p><p><strong>Methods: </strong>Ninety-three patients with TLE and matched healthy controls participated. Attention was assessed using the Attention Network Test (ANT) and eye-tracking data, while SRD severity was determined via the Pittsburgh Sleep Quality Index. Participants were categorized based on SRD severity, and attention performance across the three networks was evaluated.</p><p><strong>Results: </strong>Patients with TLE demonstrated significant attention impairments, predominantly affecting the alertness and executive control networks. SRD aggravated these deficits, particularly in the alertness network, with more severe SRD correlating with greater dysfunction. Moderate to severe SRD led to significant declines in alertness, while minimal SRD showed no substantial impact on attention performance.</p><p><strong>Conclusion: </strong>SRD exacerbates attention dysfunction in patients with TLE, particularly within the alertness network. These findings highlight the critical role of sleep quality in managing cognitive function in TLE and suggest early intervention for patients with significant SRD to improve outcomes.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"106731"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the relationship between work performance and nonrestorative sleep among daytime workers with and without insomnia symptoms.","authors":"Yuta Takano, Rui Ibata, Naho Machida, Mizuki Bando, Isa Okajima","doi":"10.1016/j.sleep.2025.106702","DOIUrl":"10.1016/j.sleep.2025.106702","url":null,"abstract":"<p><strong>Objective: </strong>Insomnia and nonrestorative sleep are associated with presenteeism, which is an indicator of work performance and a predictor of absenteeism. However, the mechanisms by which insomnia symptoms and nonrestorative sleep are associated with presenteeism remain unclear.</p><p><strong>Methods: </strong>This study included 1093 daytime workers categorized into four groups: the combination group, defined as having both insomnia symptoms and nonrestorative sleep; the nonrestorative sleep group, defined as having only nonrestorative sleep; the insomnia group, defined as having only insomnia symptoms; and the healthy group, defined as having no sleep complaints. They completed self-report questionnaires on insomnia symptoms, nonrestorative sleep, and presenteeism.</p><p><strong>Results: </strong>The marginal effects of logistic regression analysis estimated that the probability of presenteeism in the combination group was higher by 42, 29, and 28 % compared with the healthy, insomnia, and nonrestorative sleep groups, respectively. The probability of presenteeism was 15 % higher in the nonrestorative sleep group and 13 % higher in the insomnia group than in the healthy group. Network analysis determined that a bad mood upon waking-up, lack of readiness to start the day upon waking-up, low mental alertness upon waking-up, daytime dysfunction, low well-being, and poor sleep quality were associated with presenteeism in the combination group. A feeling of tiredness upon waking-up was associated with presenteeism in the nonrestorative sleep group. Grouchiness upon waking-up was associated with presenteeism in the insomnia group.</p><p><strong>Conclusion: </strong>When addressing presenteeism, the feeling of restfulness upon waking-up and during daytime activities should be considered, rather than just nocturnal sleep.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"106702"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between clinical or polysomnographic features and the risk of continuous positive airway pressure therapy termination in patients with obstructive sleep apnea: a 5-year cohort study.","authors":"Perrine Petit, Sébastien Baillieul, Marie Destors, Maëlle Guellerin, Rita Clin, Sébastien Bailly, Thi Hong Van Ngo, Jean-Louis Pépin, Renaud Tamisier","doi":"10.1016/j.sleep.2025.106720","DOIUrl":"10.1016/j.sleep.2025.106720","url":null,"abstract":"<p><strong>Background: </strong>Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea (OSA). Despite CPAP recognized benefits, the 3-year CPAP termination rate in France is 47.7 %, with sex, age, and comorbidities identified as significant predictors of therapy termination. The contribution of symptoms, OSA severity and objective sleep parameters to CPAP termination remains to be investigated.</p><p><strong>Methods: </strong>This single-center study used real-life data from a tertiary university for patients diagnosed with OSA and started on CPAP. Data were prospectively collected and linked to CPAP telemonitoring data from a single healthcare provider. CPAP termination was defined as the date when the device was returned to the healthcare provider by the patient.</p><p><strong>Results: </strong>A total of 637 patients were included. Overall CPAP termination rates at 1, 3 and 5 years were 17.1 %, 26.8 % and 28.9 % respectively. On multivariable analysis CPAP continuation was significantly associated with male sex (hazard ratio [95 % confidence interval] 0.71 [0.52-0.97]; p = 0.03), OSA severity (severe vs. mild: 0.46 [0.25-0.86]; p < 0.001; severe vs. moderate: 0.57 [0.42-0.77]; p < 0.001) and longer total sleep time at diagnosis (0.99 [0.96-1.0]; p = 0.049). CPAP termination was significantly associated with a higher mean oxygen saturation (1.20 [1.10-1.31]; p < 0.001).</p><p><strong>Conclusions: </strong>Clinical and polysomnographic phenotyping is useful in risk stratification for prediction of CPAP termination. Sleep quality metrics at diagnosis are among the key predictors of CPAP termination and should inform the personalization of follow-up management pathways.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"106720"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered functional brain networks in isolated REM sleep behavior disorder during phasic REM sleep.","authors":"Kang-Min Choi, Tae-Gon Noh, Jun-Sang Sunwoo, Jung-Ick Byun, Ki-Young Jung","doi":"10.1016/j.sleep.2025.106724","DOIUrl":"10.1016/j.sleep.2025.106724","url":null,"abstract":"<p><strong>Study objectives: </strong>Isolated REM sleep behavior disorder (iRBD) is characterized by vivid, emotionally charged, and often aggressive dreams, yet the underlying neural correlates remain poorly understood. This study aimed to investigate alterations in functional brain networks during REM sleep in iRBD patients using electroencephalogram (EEG), which is potentially associated with their dream characteristics.</p><p><strong>Methods: </strong>We analyzed EEG data from 13 drug-naïve iRBD patients and 10 healthy controls (HCs) during phasic and tonic REM sleep. Source-level functional connectivity was computed across 14 cortical regions associated with dream generation, and network topology was evaluated using graph theory metrics.</p><p><strong>Results: </strong>iRBD patients showed significantly increased gamma-band functional connectivity during phasic REM sleep (p = 0.003, network-based statistic). This hyperconnectivity correlated with reduced REM atonia (RAI; R = -0.725, p = 0.007) and trended with increased dream-related symptom severity. Key network hubs included the posterior cingulate cortex (PCC) and right inferior parietal lobule (rIPL)-core nodes of the default mode network-implicated in self-referential and spatial processing. Additionally, increased connectivity between rIPL and salience-motor circuits (anterior cingulate cortex, insula, and M1) may underlie emotional overactivation and aggressive dream content.</p><p><strong>Conclusion: </strong>Our findings suggest that gamma-band hyperconnectivity during phasic REM sleep reflects altered 'dream-related network' dynamics in iRBD, potentially contributing to the intensity and emotional valence of dream experiences. This study provides preliminary evidence that functional network alterations during REM sleep may shape dream characteristics in iRBD, offering new perspectives on its neurophysiological basis.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"134 ","pages":"106724"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ischemia-modified albumin and cardiovascular risk in obstructive sleep apnea and acute coronary syndrome. Long term follow-up after treatment from the ISAACC study","authors":"Pilar Resano-Barrio ,&nbsp;Esther Gracia-Lavedan ,&nbsp;Esther Solano-Pérez ,&nbsp;Belén García-Mediano ,&nbsp;Carolina Cubillos-Zapata ,&nbsp;Elena Díaz-García ,&nbsp;Sofía Romero-Peralta ,&nbsp;María Castillo-García ,&nbsp;Ferran Barbé ,&nbsp;Francisco García-Rio ,&nbsp;Manuel Sánchez-de-la-Torre ,&nbsp;Olga Mediano","doi":"10.1016/j.sleep.2025.106804","DOIUrl":"10.1016/j.sleep.2025.106804","url":null,"abstract":"<div><h3>Introduction</h3><div>In the context of the prevailing interest in biomarkers that can assess cardiovascular (CV) risk in obstructive sleep apnea (OSA), ischemia-modified albumin (IMA) is proposed as a potential risk predictor.</div></div><div><h3>Objectives</h3><div>To evaluate whether IMA levels predict recurrent CV events in patients with acute coronary syndrome (ACS) and OSA, and whether continuous positive airway pressure (CPAP) treatment modifies this risk.</div></div><div><h3>Methods</h3><div>This <em>post hoc</em> analysis is based on data from the ISAACC study, including 1.011 non-sleepy patients with an ACS. During hospitalization for ACS, a sleep study was conducted and blood samples for IMA determination were obtained. Patients were categorized by their apnea–hypopnea index (AHI) in non-OSA (AHI &lt;15 events/h) or OSA group (AHI ≥15 events/h). “Low” or “high” IMA levels were established based on the median value (⩽ 34.1 U/L or &gt; 34.1 U/L, respectively). The OSA group was randomized to either CPAP or usual care. The recurrence of CV events was evaluated over a 36-months follow-up.</div></div><div><h3>Results</h3><div>Adjusted cox regression models showed that the OSA group with high IMA level had a significantly reduced risk for CV event recurrence compared with the non-OSA group (HR [95 % CI] 0.59 [0.38–0.93], p = 0.024). In the OSA group with high IMA level, CPAP treatment did not significantly reduce CV recurrence.</div></div><div><h3>Conclusions</h3><div>OSA was associated with higher IMA levels in patients with ACS. Interestingly, patients with both OSA and high IMA experienced fewer CVEs during follow-up. CPAP treatment demonstrated a non-significant risk reduction in patients with low IMA, whereas no effect was noted in those with high IMA.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"136 ","pages":"Article 106804"},"PeriodicalIF":3.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EP300 as a potential mediator of stress-induced sleep disruption through blood-brain barrier dysfunction and neuroinflammation","authors":"Yaru Wang ,&nbsp;Xiaochen Zhang ,&nbsp;Li-Ming Jin ,&nbsp;Xiaoyun Yang ,&nbsp;Kuizhang Han ,&nbsp;Jiayi Ma ,&nbsp;Yiren Wang ,&nbsp;Yongjun Chen ,&nbsp;Lin Yao","doi":"10.1016/j.sleep.2025.106802","DOIUrl":"10.1016/j.sleep.2025.106802","url":null,"abstract":"<div><div>Sleep disorders (SDs) are complex and multigenic, and their pathogenesis remains unclear. This study sought to identify key genes influencing SDs to offer new perspectives on understanding, preventing, and treating the disorder. Differential expression and weighted gene co - expression network analyses were employed to find susceptibility modules and hub genes related to SDs. The Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analyses were used to explore the functions and mechanisms of these hub genes. Mendelian randomization was carried out to assess the causal relationship between <em>EP300</em> and SDs. We identified a total of 371 key genes associated with multiple biological processes. Five hub genes were identified, and a positive correlation between <em>EP300</em> and SD risk was confirmed. In a mouse model of chronic unpredictable stress with sleep architecture disturbance, bioinformatics findings were validated using qPCR experiments and single-cell RNA sequencing of the prefrontal cortex. We found that <em>EP300</em> expression was significantly increased in microglia of the model mice, coinciding with blood-brain barrier disruption and elevated <em>IL-1β</em> mRNA expression. This study first revealed the potential role of <em>EP300</em> in SD.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"136 ","pages":"Article 106802"},"PeriodicalIF":3.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep disorders in children with neurodevelopmental disorders: Comparative actigraphy and questionnaire assessment in ASD, ADHD, and controls","authors":"Sara Pinghini ,&nbsp;Lucio Giordano ,&nbsp;Francesca Banditelli ,&nbsp;Rossana Bucci ,&nbsp;Anna Eusebi ,&nbsp;Elena Filippini ,&nbsp;Michela Gritti ,&nbsp;Paola Mattei ,&nbsp;Davide Nocita ,&nbsp;Elisa Maria Fazzi ,&nbsp;Giuseppe Milito","doi":"10.1016/j.sleep.2025.106794","DOIUrl":"10.1016/j.sleep.2025.106794","url":null,"abstract":"<div><h3>Background</h3><div>Sleep disturbances are highly prevalent in children with neurodevelopmental disorders (NDD), yet few studies have combined objective and subjective measures. The objectives of this study were to evaluate sleep patterns and sleep hygiene in children with ADHD and ASD compared age-matched typically developing children, using both parent-reported questionnaires and actigraphy, to assess the concordance between these measures, and to determine the clinical applicability of actigraphy in this population.</div></div><div><h3>Methods</h3><div>Sixty children with NDD (30 ASD, 30 ADHD) and 40 typically developing controls, matched for age, underwent seven nights of actigraphic recording. Parents completed the Sleep Disturbance Scale for Children (SDSC) and Family Inventory of Sleep Habits (FISH).</div></div><div><h3>Results</h3><div>Actigraphy was well tolerated in the NDD group (88 %), consistent with previous findings. Compared to TD controls, children with NDDs showed significantly higher SDSC scores (p &lt; 0.001) and poorer actigraphic sleep parameters, including lower sleep efficiency (82.0 % vs 87.3 %, p &lt; 0.001) and longer wake after sleep onset (78.8 vs 52.7 min, p &lt; 0.001). Concordance between actigraphy and SDSC was limited (≈53 % in NDD; 15 % in TD). No significant group differences were found in sleep hygiene, although FISH scores correlated with selected actigraphic parameters only in controls.</div></div><div><h3>Conclusions</h3><div>Sleep disturbances are highly prevalent in NDD, and actigraphy is a reliable, well-tolerated tool for clinical assessment. Given the limited agreement between actigraphy and questionnaires, multimethod approaches may be necessary. Actigraphy should be considered for integration into routine clinical practice to improve sleep evaluation in pediatric NDD populations.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"136 ","pages":"Article 106794"},"PeriodicalIF":3.4,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Galectin-3 as a potential predictor of chronic insomnia and its association with NLRP3 inflammasome activation in chronic migraine: A case-control study","authors":"Wubing Zhou","doi":"10.1016/j.sleep.2025.106793","DOIUrl":"10.1016/j.sleep.2025.106793","url":null,"abstract":"<div><h3>Background</h3><div>Chronic insomnia (CI) commonly co-occurs with chronic migraine (CM), and neuroinflammation may underlie this association. Galectin-3, a pro-inflammatory mediator, has been implicated in migraine and sleep regulation, but its role in CM-related insomnia and its link to NLRP3 inflammasome activation remain unclear.</div></div><div><h3>Methods</h3><div>We conducted a case-control study of 150 CM patients, categorized by CI status using ICSD-3 criteria and Pittsburgh Sleep Quality Index (PSQI). Clinical features, psychological assessments, and plasma biomarkers (Galectin-3, NLRP3, IL-1β) were measured. Logistic regression, multiple linear regression, mediation analysis, and ROC curves evaluated associations and diagnostic performance.</div></div><div><h3>Results</h3><div>Compared with CM without insomnia (CM-nCI), CM with insomnia (CM-CI) showed higher Galectin-3 (18.69 ± 2.95 vs. 13.41 ± 2.48 ng/mL), NLRP3 (6.72 ± 1.24 vs. 4.02 ± 1.14 ng/mL), and IL-1β (5.39 ± 1.27 vs. 3.71 ± 0.87 pg/mL; all P &lt; 0.001). Galectin-3 independently predicted CI (adjusted OR = 1.393; 95 % CI: 1.153–1.681; P &lt; 0.001). Mediation analysis indicated partial mediation by NLRP3 and IL-1β (41.4 % and 36.2 %, respectively). ROC analysis demonstrated good discrimination (AUC = 0.888; cutoff = 15.85 ng/mL; sensitivity = 84.0 %; specificity = 82.0 %). Galectin-3 correlated with PSQI, anxiety, depression, migraine impact, and inflammatory markers after adjustment (all P &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Elevated plasma Galectin-3 is strongly associated with CI in CM and shows good predictive value. Its relationship with NLRP3 and IL-1β suggests a shared neuroinflammatory pathway, highlighting Galectin-3 as a potential biomarker for risk stratification and targeted management of CM patients with insomnia.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"136 ","pages":"Article 106793"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}